Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Change in Accured Expenses: 2019-2024

Historic Change in Accured Expenses for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $6.5 million.

  • 4D Molecular Therapeutics' Change in Accured Expenses fell 38.53% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year decrease of 68.64%. This contributed to the annual value of $6.5 million for FY2024, which is 93.53% up from last year.
  • As of FY2024, 4D Molecular Therapeutics' Change in Accured Expenses stood at $6.5 million, which was up 93.53% from $3.4 million recorded in FY2023.
  • In the past 5 years, 4D Molecular Therapeutics' Change in Accured Expenses registered a high of $6.5 million during FY2024, and its lowest value of $689,000 during FY2021.
  • For the 3-year period, 4D Molecular Therapeutics' Change in Accured Expenses averaged around $4.1 million, with its median value being $3.4 million (2023).
  • In the last 5 years, 4D Molecular Therapeutics' Change in Accured Expenses tumbled by 63.72% in 2021 and then soared by 260.67% in 2022.
  • 4D Molecular Therapeutics' Change in Accured Expenses (Yearly) stood at $1.9 million in 2020, then tumbled by 63.72% to $689,000 in 2021, then soared by 260.67% to $2.5 million in 2022, then surged by 35.65% to $3.4 million in 2023, then surged by 93.53% to $6.5 million in 2024.